09:00 AM EST - BioVaxys Technology Corp. : Announced today that it has entered into a major sponsored research collaboration with The Ohio State University to further develop BioVaxys' haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine. This is the second research collaboration in the SARS-CoV-2 field between BioVaxys, a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect and prevent emerging infectious diseases; and Ohio State, a leading global academic research institute in the fight against SARS-CoV-2. Ohio State's Wexner Medical Center serves as a site for SARS-CoV-2 multicenter clinical trials. BioVaxys Technology Corp.
shares C.BIOV are trading up 0.02 cents at $0.26.
